Calidi Biotherapeutics, Inc. SEC filings CLDI
Calidi Biotherapeutics, Inc. has 406 filings in SEC EDGAR's recent list, going back to May 17, 2021. Its latest annual report, Form 10-K, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 25, 2026 (listing notice, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 20, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| EFFECT | Filing | Jul 25, 2025 | — |
| CORRESP | Letter to the SEC | Jul 24, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 22, 2025 | — |
| EFFECT | Filing | Jul 11, 2025 | — |
| CORRESP | Letter to the SEC | Jul 10, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2025 | — |
| DRS | Filing | Jul 2, 2025 | — |
| EFFECT | Filing | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Feb 6, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2025 | — |
| EFFECT | Filing | Dec 27, 2024 | — |
| CORRESP | Letter to the SEC | Dec 26, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2024 | — |
| 25-NSE | Delisting notice | Oct 28, 2024 | — |
| EFFECT | Filing | Oct 10, 2024 | — |
| CORRESP | Letter to the SEC | Oct 8, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2024 | — |
| D | Filing | Jun 6, 2024 | — |
| EFFECT | Filing | Apr 15, 2024 | — |
| CORRESP | Letter to the SEC | Apr 15, 2024 | — |
| CORRESP | Letter to the SEC | Apr 15, 2024 | — |
| CORRESP | Letter to the SEC | Apr 15, 2024 | — |
| CORRESP | Letter to the SEC | Apr 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 10, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| D | Filing | Mar 21, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2024 | — |
| EFFECT | Filing | Jan 19, 2024 | — |
| CORRESP | Letter to the SEC | Jan 17, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2024 | — |
| CORRESP | Letter to the SEC | Jan 8, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2023 | — |
| CORRESP | Letter to the SEC | Dec 12, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2023 | — |
| 25-NSE | Delisting notice | Sep 13, 2023 | — |
| 425 | Filing | Aug 24, 2023 | — |
| 425 | Filing | Aug 22, 2023 | — |
| 425 | Filing | Aug 21, 2023 | — |
| 425 | Filing | Aug 16, 2023 | — |
| NT 10-Q | Filing | Aug 15, 2023 | Jun 30, 2023 |
| SEC STAFF LETTER | Filing | Aug 8, 2023 | — |
| 425 | Filing | Aug 7, 2023 | — |
| EFFECT | Filing | Aug 4, 2023 | — |
| CORRESP | Letter to the SEC | Aug 3, 2023 | — |
| SEC STAFF LETTER | Filing | Jul 26, 2023 | — |
| CORRESP | Letter to the SEC | Jul 24, 2023 | — |
| 425 | Filing | Jul 18, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 14, 2023 | — |
| CORRESP | Letter to the SEC | Jun 30, 2023 | — |
| 425 | Filing | Jun 23, 2023 | — |
| UPLOAD | Letter from the SEC | May 18, 2023 | — |
| CORRESP | Letter to the SEC | May 8, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2023 | — |
| CORRESP | Letter to the SEC | Apr 13, 2023 | — |
| 425 | Filing | Apr 13, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 9, 2023 | — |
| 425 | Filing | Feb 10, 2023 | — |
| 425 | Filing | Jan 9, 2023 | — |
| 25 | Filing | Nov 25, 2022 | — |
| CERT | Nyse american certification | Nov 14, 2022 | — |
| 8-A12B | Filing | Nov 14, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2022 | — |
| CORRESP | Letter to the SEC | Aug 15, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2022 | — |
| EFFECT | Filing | Sep 9, 2021 | — |
| CERT | Nyse certification | Sep 9, 2021 | — |
| 8-A12B | Filing | Sep 9, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| CORRESP | Letter to the SEC | Sep 7, 2021 | — |
| CORRESP | Letter to the SEC | Sep 3, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2021 | — |
| DRS/A | Filing | Jul 19, 2021 | — |
| DRS | Filing | May 17, 2021 | — |
Showing 81 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLDI (NYSE), CLDWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855485
- Former names
- Calidi Biotherapeutics, Inc. (until Sep 25, 2026); First Light Acquisition Group, Inc. (until Sep 19, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.